Phase I-II Study of Carfilzomib, Lenalidomide, Dexamethasone, and Panobinostat, Ca-R-Pa-Diem, as Induction Therapy for Newly Diagnosed, Untreated, Transplant-Eligible, Multiple Myeloma Patients
Withdrawn prior to enrolment
Phase of Trial: Phase I/II
Latest Information Update: 28 Apr 2017
At a glance
- Drugs Carfilzomib (Primary) ; Dexamethasone (Primary) ; Dexamethasone (Primary) ; Lenalidomide (Primary) ; Panobinostat (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- 24 Apr 2017 Planned End Date changed from 31 Dec 2020 to 1 Dec 2020.
- 24 Apr 2017 Planned primary completion date changed from 30 Sep 2020 to 1 Sep 2020.
- 24 Apr 2017 Planned initiation date changed from 30 Jun 2017 to 1 Jun 2017.